Swog Cancer Research Network

This study tested two different drug combinations in 240 people with advanced colorectal cancer that has a specific genetic change called HER2 amplification. One group received a combination of targeted antibodies (trastuzumab and pertuzumab), while the other received a standard …

This study tested whether a new drug (TAK-700) combined with standard hormone therapy helps men with newly diagnosed metastatic prostate cancer live longer compared to the usual combination of bicalutamide and hormone therapy. Over 1,300 men took part. The goal was to see which a…

This study tested two different treatments for people newly diagnosed with a slow-growing type of lymphoma (follicular non-Hodgkin's lymphoma). Both treatments combined standard chemotherapy (CHOP) with a targeted antibody — either rituximab or a radioactive antibody called tosit…

This phase 3 trial tested whether taking everolimus for a year after kidney cancer surgery could prevent the cancer from coming back. Over 1500 patients with high-risk kidney cancer participated. The study compared everolimus to a placebo to see if it improved recurrence-free sur…

This study tested adding elotuzumab to a standard three-drug regimen for people with newly diagnosed, high-risk multiple myeloma. The goal was to find the safest dose and see if the combination could delay cancer progression. 142 participants received either the standard therapy …

This study tested whether adding a third chemotherapy drug (nab-paclitaxel) to the standard two-drug treatment helps people with advanced bile duct or gallbladder cancer live longer. 452 adults with newly diagnosed, advanced disease took part. The goal was to see if the three-dru…

This study tested whether adding the drug ramucirumab to standard chemotherapy (carboplatin and paclitaxel) helps people with advanced thymic cancer that cannot be surgically removed. The trial included 21 patients with cancer that had spread or returned. The goal was to see if t…

This study tested a drug called isatuximab in 43 people with AL amyloidosis whose disease came back or didn't respond to prior treatments. AL amyloidosis is a rare condition where abnormal proteins build up in organs. Isatuximab is a lab-made antibody that helps the immune system…